Foundation Fighting Blindness USA strongly supports a bipartisan bill introduced late Wednesday, July 18, 2018 in the U.S. House of Representatives that holds enormous promise for saving and restoring the vision of the 4 million adults and almost half-a-million children in the U.S. who are blind or have severely impaired vision from a variety of eye diseases and conditions, including inherited retinal diseases and age-related macular degeneration.
Retina International is delighted to announce the appointment of Sarah McLoughlin as Science Communication Officer.
Sarah will be working on the implementation of RI’s communications strategy where she will play a key role in one of the organisations primary objectives: delivery of the latest information on relevant developments in research and innovation to members and stakeholders.
On World Health Day 2018, April 7th, the World Health Organization marks its 70th anniversary. Over the past seven decades, WHO has spearheaded efforts to rid the world of diseases like smallpox and to fight against deadly habits like tobacco use.
In 2018 World Health Day is dedicated to one of WHO’s founding principles:
“The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, and political belief, economic or social condition.”
The ERN-EYE organized its third meeting on March 26th to 27th in Tallinn, Estonia. The Annual General Meeting was attended by 60 people from Health Care Providers (HCP) from the 13 member countries in the network, as well as invited speakers.
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A 12
Foundation Fighting Blindness and ProQR have entered into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program into the clinic. QR-421a received orphan drug designation from the FDA.
On Wednesday January 3rd 2018, Spark Therapeutics INC announced a series of payment models designed to help the process of patient access to its new gene therapy LUXTURNA in the United States, which is the only country where the once in a lifetime therapy is currently approved. The company also announced the cost of the treatment.
On World Sight Day, eye care organisations around the world take note of new data that shows that global eye care efforts are at serious risk of being overwhelmed—unless we act now.
New data published in the Lancet Global Health shows that decades of declining “avoidable blindness”—those with uncorrected refractive errors and cataract—is plateauing, and is projected to increase between 2015 and 2050.
DIAGNOSIS IS KEY!
AMD (Age-related Macular Degeneration) is a condition that affects central vision and is associated with aging. It is important to note however that deteriorating vision is not an inevitable part of the aging process but the result of a particular condition that can, when diagnosed early enough be successfully treated.
In the over 50s, AMD is the leading cause of sight loss.